Innovative Cat Allergy Vaccine Enters Human Clinical Trials

Angany Inc. has received clearance from the U.K.’s Medicines and Healthcare Products Regulatory Agency to conduct clinical trials on its innovative therapeutic vaccine, ANG-101, designed to treat human cat allergies.

ANG-101, a disruptive disease-modifying vaccine for cat allergies, utilizes proprietary eBioparticle-Potentiated Immunotherapy™ technology. Its active immunotherapeutic ingredient, a unique 140 nm enveloped bioparticle (eBioparticle™), closely resembles a virus in shape and size. It features thousands of copies of the cat major allergen Fel d 1 on its surface.

This groundbreaking clinical study represents a first-in-human, open-label evaluation of ANG-101’s safety, allergenicity, and immunogenicity. It will involve adult patients with cat dander allergies.

Leading clinical allergy experts from Imperial College London, Professor Stephen Durham and Dr. Guy Scadding, will oversee this early-stage clinical trial.

Professor Durham stated in an October 5, 2023 press release, “The potential treatment of cat allergy using an auto-adjuvanted vector builds upon its known ability to induce strong allergen-specific IgG antibody responses, as observed in animal models.”

Angany’s therapeutic vaccines, unlike prophylactic vaccines, are a novel generation of immunotherapy biologics designed to address established pathologies. They aim to restore or enhance natural immune mechanisms, providing sustainable immune protection and vigilance.

According to the Asthma and Allergy Foundation of America, cat and dog allergies affect 10 to 20% of the world’s population. These allergies are not triggered by the pet’s hair, fur, or feathers but by the proteins found in their dander, saliva, and urine.